Neoleukin Therapeutics (NASDAQ:NLTX) Downgraded by Zacks Investment Research to “Hold”
Neoleukin Therapeutics (NASDAQ:NLTX – Get Review) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note released on Tuesday, Zacks.com reports.
According to Zacks, “Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in the creation of next-generation immunotherapies using de novo protein design technology. The Company’s product candidate consists of NL-201 which is clinical phase. Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals Inc., is based in Seattle, USA.”
Other stock analysts have also recently released reports on the company. Piper Sandler cut her price target on Neoleukin Therapeutics from $30.00 to $25.00 and set an “overweight” rating on the stock in a Wednesday, March 2 report. HC Wainwright restated a “buy” rating and issued a $22.00 price target on Neoleukin Therapeutics shares in a Tuesday, January 11 report.
NASDAQ:NLTX shares opened at $2.28 on Tuesday. The stock’s 50-day moving average price is $3.44 and its two-hundred-day moving average price is $5.47. Neoleukin Therapeutics has a 12-month low of $2.21 and a 12-month high of $13.40. The company has a market capitalization of $96.89 million, a price-earnings ratio of -2.07 and a beta of 1.12.
Institutional investors have recently increased or reduced their stake in the company. Candriam Luxembourg SCA increased its stake in Neoleukin Therapeutics shares by 67.6% during the 3rd quarter. Candriam Luxembourg SCA now owns 858,173 shares of the company valued at $6,204,000 after purchasing an additional 346,160 shares during the period. Morgan Stanley increased its equity stake in Neoleukin Therapeutics by 82.5% during the 2nd quarter. Morgan Stanley now owns 631,008 shares of the company valued at $5,824,000 after purchasing an additional 285,337 shares during the period. Renaissance Technologies LLC increased its equity stake in Neoleukin Therapeutics by 31.4% during the third quarter. Renaissance Technologies LLC now owns 756,892 shares of the company valued at $5,472,000 after purchasing an additional 180,900 shares during the period. Bank of America Corp DE increased its equity stake in Neoleukin Therapeutics by 481.9% during Q2. Bank of America Corp DE now owns 184,214 shares of the company valued at $1,700,000 after purchasing an additional 152,555 shares during the period. Finally, Millennium Management LLC increased its stake in Neoleukin Therapeutics shares by 77.6% during the 3rd quarter. Millennium Management LLC now owns 280,517 shares of the company valued at $2,028,000 after purchasing an additional 122,546 shares during the period. Institutional investors hold 60.48% of the company’s shares.
About Neoleukin Therapeutics (Get a rating)
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which uses computational methods to design protein therapeutics de novo. The company addresses important medical needs in oncology, inflammation and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate binding to alpha receptors.
Get a Free Copy of Zacks Research Report on Neoleukin Therapeutics (NLTX)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Neoleukin Therapeutics right now?
Before you consider Neoleukin Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Neoleukin Therapeutics wasn’t on the list.
Although Neoleukin Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here